Member Info for CHELSEA7

"""Look at the results of the clinical trials for 201 and 401?""" You make me laugh, post them then.

Six years of RNSs, and all they talk about is dose escalation!!! No mention of talks.

Your posts are scary, totally fictional, and as you posted tell us about the results for 201. IMHO you are either a paid ramper or a nutter!!!

jonjo, there isn"t one. That was my point in posting the RNSs. ATB

Volume 76k

Buys 61k

Sells 15k

Just two trades on NEX, both buys, 7k total.

jonjo, know how you feel, but if they are in talks and subject to NDAS in fairness there is nothing they can say. Anyway wish you luck. Night

Thanks woody, you have joined fourteen in filtering me. The truth hurts.

To be honest in seven years never had anybody insult me for researching RNSs. In fairness to the BOD, and something I could see easily, much of what has become fact, IMHO is actually rampers distorting what the BOD have actually said. Anyone who dares realise that, gets their posts removed.

BTW, I don"t believe you and fourteen have filtered me at all, just an out from never answering any questions put to you. Unlike what you say if a Pharma wants to buy VAL because they see genuine potential I would be the first to congratulate holders here, like I did in my first post 9 months ago, only to be wished dead by numerous people when I gave reason for my interest here.

Regardless mine is just my opinion, and yes I have researched this far more than I ever intended too. Take care, goodnight, will post up the RNSs on 401 very soon, and you can make your own minds up.

Woody you posted..............................

""I haven't read your previous RNS collection. Ive read them all previously so I dont need a cynic to give me his interpretation"""

Interesting you should say that, I spent time going through the RNSs that you guys swear by. Didn"t even really give my opinions, so I presume what your saying is your interpretation after reading the information posted in VAL RNSs year after year, makes you feel cynical.

I agree , it doesn"t make for good reading, it is the same news regurgitated year after year, often followed by a placing. I would complain to VAL if I were you, rather than criticise me. Balance my friend..

Hang on, I am just finishing off 401!!!!

It gets better, lol.

Not surprised, you took me to task over lack of communication a few months back, got very personal too, but when others posted the same, said nothing. Welcome to your opinion, we all have them,

CEREUS, sorry to hear that. Perhaps a few should read the facts by RNS. GL anyway and thanks for your honesty

Tozerk, you say...…………"""""They are in talks on 401 and 201 I think""""

One reason I posted my 02.29 was because of comments like that. Where does it say VAL are in talks?

Interesting entry on October 2nd, a good informative read...………………………..

https://twitter.com/hashtag/cancervaccines?src=hash

Glad you replied Ivy, being honest it wasn't just a dig aimed at you, I have mentioned the same to another who brought up the subject. Surprised TF even thought it referred to him, but just shows, post one thing and at least two people think it refers to them. Sorry for the dig, but surprised with your post, that's all.

It is pretty obvious to me that it only becomes a problem if it turns out like another Biotech I mentioned, and I was also surprised that you were quite dismissal of JCs involvement in the collaborations RG signed off with. Guess we all have opinions, still surprises me that no end how we see the same thing we see it so differently. That is relevant more to this share than many others.No offence meant, my best wishes to you.

TW Latest...……….…………Tom Winnifrith Bearcast: Next stop for Musk & Tesla ( jail & $0?) & what really happened at Premaitha will shock you""

I posted this last week, and received no responses. Would like to hear from those who say "it is in the RNS".

The reason for me posting this, after being branded a deramper and unresearched is I have gone through ALL the RNSs over the years, and personally see little progress, many promises, and very little comment as to being in "serious discussions". It is why I have been so negative about VAL.

Unlike some, your comments are appreciated. Whilst I live by never buying a share from talk on a BB, I can think of a few I have bought from good answers and posts from those invested, which have persuaded me to see it differently. That in itself is what I believe a good BB is all about.

You say JC is a remote chair, which sounds to me as if he picks up his money for doing nothing.

My only point is that there is zero evidence that the man is doing nothing, and zero evidence that he is not behind the current stratagy, which to me is a perfect pre-cursor to commercial deals.

The time that I will ask questions is if Directors remunaration reaches the proportions of VAL, where IMHO and consistent with another post I have landed there this morning, reaches levels where shareholders are funding them constantly, with very little work being done on the pipeline. I really do not thimk these packages are anything but in like with our standing, and the time to question them is if nothing materialises and the company cannot make the move to being self funded. My only gripe has been what i see as lack of PI relations in informing us of progress, particularly after a fairly large placing and an OO which i subscribed too. That will go, if as I think we are in discussions, serious ones, with our collaborators on a commercial deal to pay for Moditope trials at least. As i have said, that is very plausible and i would understand the silence.

Close to a deal??????..................................
11th January 2017 - Building on these positive results, ValiRx is adding additional clinical sites to participate in the dose-escalating, therapeutically relevant phase of the trial to arrive at the maximum tolerated dose. And Satu added – ‘We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and tolerability shown to date to meet the needs of those patients currently under-served by current therapies. ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value.’
So, just the six years of dose escalation so far...but then, on 28 February 2017 – ‘PEER-REVIEWED PUBLISHED ARTICLES SUPPORTING VALIRX & VALISEEK'S ANTI-CANCER TECHNOLOGY’, followed 24 hours later by (1st Mar 2017) "VALIRX RAISE £1.16M TO ACCELERATE CLINICAL TRIALS IN VAL201 & VAL401" - PLACING AND PROPOSED SUBSCRIPTION
20 September 2017 - VAL201 update – ‘The Company notes speculation as to the status of its VAL201 clinical trial and confirms that the trial is ongoing and looks forward to updating the market in due course.’ (That’s not an update is it?)

6th September 2018 Clinical Update – Dr Satu Vainikka, CEO of ValiRx, commented: "... VAL201 is increasingly showing its therapeutic potential...’

I have left out the placings – they can be counted if I get a lot more time. And nowhere in any RNS is there mention of discussions, advanced or even preliminary, or approaching deals, or interested parties, or patient numbers, or survival rates, or of much at all really. So VAL201 has been in development for 7 and a half years and all that they can say with confidence is that it hasn’t killed anyone. Now do you wonder why the share price graph looks like an Olympic ski slope?

So Val are in talks!!!.................

28th Jul 2011 ...in the studies thus far, VAL201 has been shown to prevent cancerous growth in live models
2nd Apr 2012
Satu quote - "The Placing ... will allow the Company to accelerate translational and developmental studies on its lead compounds, VAL201 and VAL101, and will assist the Company in the progression of these compounds from pre-clinical and into Phase I clinical trials."

24th October 2013 – ‘...this trial to commence in Q1 2014. The expanded trial is anticipated to yield early results within 8 weeks of commencement.’

1st Apr 2014 – ‘The Company is informed by the CTPT that it could proceed now, but the CTPT have recommended that a further stability and sterility study be completed...’
3rd Nov 2014 - 201 update - Dr Satu Vainikka, CEO of ValiRx, commented: "I am pleased that the trial is progressing as announced and the whole team is delivering according to the schedule in the Company's plan".
26th November 2014 ‘...the Company is expecting to have the first results relating to safety and tolerability from the first subjects during Quarter 1, 2015.’
24th Feb 2015 ‘...pleased to announce that its lead compound, VAL201 was safe and well tolerated at the doses tested.’

25th Jun 2015 The trial is now advancing through the planned dose escalation...

21st July 2015 ‘...the next dose escalation has been approved, which may prove sufficient to show anti-tumour activity.’

16th February 2016 ‘Final dose escalation approved’ (17th Feb 2016 13:00 Placing to raise £0.5 million)

17th Mar 2016 VALIRX ENGAGES US INVESTOR RELATIONS FIRM – and...?
19th May 2016 201...has shown a high degree of safety, with no drug related significant adverse events being reported.
7th June 2016 - To date, no drug related significant adverse events have been reported. Dose escalation has reached therapeutic levels and the studies have shown early indications of efficacy. (So here we are, 30 months later and nothing. Anyway, what’s an early indication of efficacy? It either shows efficacy or it doesn’t, so that then begs the question of why call something a ‘therapeutic dose’ if the best it does is offer an ‘early indication’?)
29th November 2016 – Clinical update - ....VAL201, continues to perform well in its "Phase I/II dose escalation study to assess safety and tolerability of VAL201.... The study is a titration, open label, dose-escalation trial designed to identify a maximum tolerated or administered dose (MTD/MAD).
11th January 2017 - Building on these positive results, ValiRx is adding additional clinical sites to participate in the dose-escalating, therapeutically relevant phase of the trial to arrive at the maximum tolerated dose. And Satu added – ‘We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and tolerability shown to date to meet the needs of those patients currently under-served by current therapies. ValiRx is entering a

Very true. And who is to say the perceived failure for funding in America has not been or will not be instrumental in the future.

We have and are going through a period where lak of news has been the order of the day, given that why and on what grounds should JC put under fire, when nobody knows just how much he has been doing to get us where we hope we are today.

Lets have a better week this week.

Seems like TW has support for NIPT at the moment, mind you he did for Big Sofa too. Just pleased for LTH here that IMHO they were in on the recent rise, from lows that nobody saw.

I haven"t got a position here, but GL those that have, there is much to like about the potential here. ATVB.

Sorry guys, meant to post that on NIPT. GL.